Robert F Schwabe

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9369905/publications.pdf

Version: 2024-02-01

75 14,040 41 72
papers citations h-index g-index

79 79 79 21519
all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications. Gut, 2023, 72, 736-748.	6.1	42
2	A disease-promoting role of the intestinal mycobiome in non-alcoholic fatty liver disease. Journal of Hepatology, 2022, 76, 765-767.	1.8	2
3	Liver specific, systemic and genetic contributors to alcohol-related liver disease progression. Zeitschrift Fur Gastroenterologie, 2022, 60, 36-44.	0.2	2
4	Inhibition of carnitine palmitoyltransferase 1A in hepatic stellate cells protects against fibrosis. Journal of Hepatology, 2022, 77, 15-28.	1.8	31
5	Nuclear HMGB1 protects from nonalcoholic fatty liver disease through negative regulation of liver X receptor. Science Advances, 2022, 8, eabg9055.	4.7	7
6	Effect of rifaximin on infections, acuteâ€onâ€chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFAâ€AH). Liver International, 2022, 42, 1109-1120.	1.9	20
7	TAZ-induced Cybb contributes to liver tumor formation in non-alcoholic steatohepatitis. Journal of Hepatology, 2022, 76, 910-920.	1.8	27
8	The purinergic P2Y14 receptor links hepatocyte death to hepatic stellate cell activation and fibrogenesis in the liver. Science Translational Medicine, 2022, 14, eabe5795.	5 . 8	25
9	Histone acetylation of bile acid transporter genes plays a critical role in cirrhosis. Journal of Hepatology, 2022, 76, 850-861.	1.8	17
10	\hat{l}^2 -Catenin Sustains and Is Required for YES-associated Protein Oncogenic Activity in Cholangiocarcinoma. Gastroenterology, 2022, 163, 481-494.	0.6	13
11	Breakthroughs in hepatology. Journal of Hepatology, 2022, 76, 1247-1248.	1.8	O
12	Understanding the cellular interactome of non-alcoholic fatty liver disease. JHEP Reports, 2022, 4, 100524.	2.6	35
13	Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features. Journal of Hepatology, 2021, 74, 613-626.	1.8	34
14	Maladaptive regeneration â€" the reawakening of developmental pathways in NASH and fibrosis. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 131-142.	8.2	64
15	Chimeric Antigen Receptor T Cells as Senolytic and Antifibrotic Therapy. Hepatology, 2021, 73, 1227-1229.	3 . 6	3
16	Mouse Models of Liver Fibrosis. Methods in Molecular Biology, 2021, 2299, 339-356.	0.4	23
17	A molecular single-cell lung atlas of lethal COVID-19. Nature, 2021, 595, 114-119.	13.7	411
18	Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations. Cancer Cell, 2021, 39, 866-882.e11.	7.7	159

#	Article	IF	CITATIONS
19	Tumor restriction by type I collagen opposes tumor-promoting effects of cancer-associated fibroblasts. Journal of Clinical Investigation, 2021, 131, .	3.9	144
20	Leukocyteâ€Derived Highâ€Mobility Group Box 1 Governs Hepatic Immune Responses to Listeria monocytogenes. Hepatology Communications, 2021, 5, 2104-2120.	2.0	3
21	Oncostatin M Receptor–Targeted Antibodies Suppress STAT3 Signaling and Inhibit Ovarian Cancer Growth. Cancer Research, 2021, 81, 5336-5352.	0.4	27
22	Focal adhesion kinase (FAK) promotes cholangiocarcinoma development and progression via YAP activation. Journal of Hepatology, 2021, 75, 888-899.	1.8	45
23	Macrophage MerTK Promotes Liver Fibrosis in Nonalcoholic Steatohepatitis. Cell Metabolism, 2020, 31, 406-421.e7.	7.2	141
24	c-Rel orchestrates energy-dependent epithelial and macrophage reprogramming in fibrosis. Nature Metabolism, 2020, 2, 1350-1367.	5.1	16
25	Regenerating research and life. JHEP Reports, 2020, 2, 100172.	2.6	0
26	Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis. Gastroenterology, 2020, 158, 1913-1928.	0.6	346
27	FoxM1 Induces CCl2 Secretion From Hepatocytes Triggering Hepatic Inflammation, Injury, Fibrosis, and Liver Cancer. Cellular and Molecular Gastroenterology and Hepatology, 2020, 9, 555-556.	2.3	8
28	Gut microbiome in HCC – Mechanisms, diagnosis and therapy. Journal of Hepatology, 2020, 72, 230-238.	1.8	206
29	Cholesterol Stabilizes TAZ in Hepatocytes to Promote Experimental Non-alcoholic Steatohepatitis. Cell Metabolism, 2020, 31, 969-986.e7.	7.2	117
30	SIRT6 Protects Against Liver Fibrosis by Deacetylation and Suppression of SMAD3 in Hepatic Stellate Cells. Cellular and Molecular Gastroenterology and Hepatology, 2020, 10, 341-364.	2.3	45
31	Contributions of Fibroblasts, Extracellular Matrix, Stiffness, and Mechanosensing to Hepatocarcinogenesis. Seminars in Liver Disease, 2019, 39, 315-333.	1.8	33
32	Aryl Hydrocarbon Receptor Signaling Prevents Activation of Hepatic Stellate Cells and Liver Fibrogenesis in Mice. Gastroenterology, 2019, 157, 793-806.e14.	0.6	67
33	Hyaluronan synthase $2\hat{a}\in\text{``mediated}$ hyaluronan production mediates Notch1 activation and liver fibrosis. Science Translational Medicine, 2019, 11, .	5.8	91
34	Soluble Fibers Improve Metabolic Syndrome but May Cause Liver Disease and Hepatocellular Carcinoma. Hepatology, 2019, 70, 739-741.	3.6	3
35	Embracing basic and clinical innovation in hepatology. JHEP Reports, 2019, 1, 343-344.	2.6	0
36	NLR Family Pyrin Domainâ€Containing 3 Inflammasome Activation in Hepatic Stellate Cells Induces Liver Fibrosis in Mice. Hepatology, 2019, 69, 845-859.	3.6	100

#	Article	IF	CITATIONS
37	MicroRNAâ€21 and Dicer are dispensable for hepatic stellate cell activation and the development of liver fibrosis. Hepatology, 2018, 67, 2414-2429.	3.6	64
38	Animal models of HCC – When injury meets mutation. Journal of Hepatology, 2018, 68, 193-194.	1.8	2
39	Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis. Science Translational Medicine, 2018, 10, .	5.8	151
40	Apoptosis and necroptosis in the liver: a matter of life and death. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 738-752.	8.2	364
41	HMGB1 links chronic liver injury to progenitor responses and hepatocarcinogenesis. Journal of Clinical Investigation, 2018, 128, 2436-2451.	3.9	78
42	Gut microbiota and Toll-like receptors set the stage for cytokine-mediated failure of antibacterial responses in the fibrotic liver. Gut, 2017, 66, 396-398.	6.1	7
43	Hepatocellular Carcinomas Originate Predominantly from Hepatocytes and Benign Lesions from Hepatic Progenitor Cells. Cell Reports, 2017, 19, 584-600.	2.9	102
44	The Role of Cancer-Associated Fibroblasts and Fibrosis in Liver Cancer. Annual Review of Pathology: Mechanisms of Disease, 2017, 12, 153-186.	9.6	422
45	The gut microbiome and liver cancer: mechanisms and clinical translation. Nature Reviews Gastroenterology and Hepatology, 2017, 14, 527-539.	8.2	401
46	TLR4 Deficiency Protects against Hepatic Fibrosis and Diethylnitrosamine-Induced Pre-Carcinogenic Liver Injury in Fibrotic Liver. PLoS ONE, 2016, 11, e0158819.	1.1	28
47	Opposite roles of cannabinoid receptors 1 and 2 in hepatocarcinogenesis. Gut, 2016, 65, 1721-1732.	6.1	31
48	Direct Reprogramming of Hepatic Myofibroblasts into Hepatocytes InÂVivo Attenuates Liver Fibrosis. Cell Stem Cell, 2016, 18, 797-808.	5 . 2	181
49	Negative regulation of NF-lºB p65 activity by serine 536 phosphorylation. Science Signaling, 2016, 9, ra85.	1.6	96
50	Hepatocyte TAZ/WWTR1 Promotes Inflammation and Fibrosis in Nonalcoholic Steatohepatitis. Cell Metabolism, 2016, 24, 848-862.	7.2	279
51	InÂVivo Hepatic Reprogramming of Myofibroblasts with AAV Vectors as a Therapeutic Strategy for Liver Fibrosis. Cell Stem Cell, 2016, 18, 809-816.	5.2	109
52	Epithelial Transforming Growth Factor- \hat{l}^2 Signaling Does Not Contribute to Liver Fibrosis but Protects Mice From Cholangiocarcinoma. Gastroenterology, 2016, 150, 720-733.	0.6	57
53	Contribution of Underlying Connective Tissue Cells to Taste Buds in Mouse Tongue and Soft Palate. PLoS ONE, 2016, 11, e0146475.	1.1	21
54	Serum Amyloid A Induces Inflammation, Proliferation and Cell Death in Activated Hepatic Stellate Cells. PLoS ONE, 2016, 11, e0150893.	1.1	52

#	Article	IF	Citations
55	The HMGB1/RAGE axis triggers neutrophil-mediated injury amplification following necrosis. Journal of Clinical Investigation, 2015, 125, 539-550.	3.9	307
56	High-yield and high-purity isolation of hepatic stellate cells from normal and fibrotic mouse livers. Nature Protocols, 2015, 10, 305-315.	5.5	400
57	Gremlin 1 Identifies a Skeletal Stem Cell with Bone, Cartilage, and Reticular Stromal Potential. Cell, 2015, 160, 269-284.	13.5	535
58	Origin and Function of Myofibroblasts in the Liver. Seminars in Liver Disease, 2015, 35, 097-106.	1.8	72
59	Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature, 2015, 527, 472-476.	13.7	1,498
60	Hepatocellular carcinoma originates from hepatocytes and not from the progenitor/biliary compartment. Journal of Clinical Investigation, 2015, 125, 3891-3903.	3.9	175
61	HMGB1 and injury amplification. Oncotarget, 2015, 6, 23048-23049.	0.8	8
62	NAD + Supplementation as a Novel Approach to cURIng HCC?. Cancer Cell, 2014, 26, 777-778.	7.7	5
63	High-Mobility Group Box 1 Is Dispensable for Autophagy, Mitochondrial Quality Control, and Organ Function InAVivo. Cell Metabolism, 2014, 19, 539-547.	7.2	82
64	CCL20 mediates lipopolysaccharide induced liver injury and is a potential driver of inflammation and fibrosis in alcoholic hepatitis. Gut, 2014, 63, 1782-1792.	6.1	118
65	Cell Death and Cell Death Responses in Liver Disease: Mechanisms and Clinical Relevance. Gastroenterology, 2014, 147, 765-783.e4.	0.6	587
66	Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nature Communications, 2013, 4, 2823.	5.8	1,012
67	The microbiome and cancer. Nature Reviews Cancer, 2013, 13, 800-812.	12.8	1,338
68	Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice. Hepatology, 2013, 58, 1461-1473.	3.6	468
69	Bacteria Deliver a Genotoxic Hit. Science, 2012, 338, 52-53.	6.0	28
70	Deactivation of Hepatic Stellate Cells During Liver Fibrosis Resolution in Mice. Gastroenterology, 2012, 143, 1073-1083.e22.	0.6	422
71	Targeting Liver Cancer: First Steps toward a miRacle?. Cancer Cell, 2011, 20, 698-699.	7.7	34
72	Assessing the roles of various retinoidâ€metabolizing CYP enzymes in liver disease. FASEB Journal, 2009, 23, 215.2.	0.2	0

#	Article	IF	CITATIONS
73	TLR4 enhances TGF-Î ² signaling and hepatic fibrosis. Nature Medicine, 2007, 13, 1324-1332.	15.2	1,712
74	Toll-Like Receptor Signaling in the Liver. Gastroenterology, 2006, 130, 1886-1900.	0.6	377
75	IKKβ phosphorylates p65 at S468 in transactivaton domain 2. FASEB Journal, 2005, 19, 1758-1760.	0.2	79